CODX Co-Diagnostics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1692415 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY69.1%
TTM net income YoY-47.5%
TTM EPS YoY60.1%
Revenue 3-yr CAGR-43.1%
Net income 3-yr CAGR—
Margins
Gross margin20.3%
Operating margin-5,614.3%
Net margin-5,527.6%
FCF margin-3,165.7%
EBITDA margin-5,504.0%
Returns
ROE-194.5%
ROA-165.0%
ROIC (approx.)-207.8%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets26.3%
Debt / equity0.00x
Current ratio0.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-71.6%
Payout ratio—
Capex / revenue35.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $622,489 | $3.92M | $6.81M | $34.22M | $97.89M |
| Cost of revenue | $222,377 | $999,124 | $4.18M | $5.48M | $11.57M |
| Gross profit | $400,112 | $2.92M | $2.63M | $28.74M | $86.31M |
| R&D expense | $19.14M | $20.98M | $22.96M | $17.44M | $14.96M |
| SG&A expense | $9.06M | $16.16M | $14.28M | $14.26M | $11.55M |
| Operating income | -$50.17M | -$40.08M | -$42.71M | -$26.98M | $46.06M |
| Pretax income | -$48.51M | -$37.58M | -$38.11M | -$18.85M | $45.64M |
| Income tax | -$1.62M | $57,368 | -$2.78M | -$4.61M | $8.98M |
| Net income | -$46.90M | -$37.64M | -$35.33M | -$14.24M | $36.66M |
| EBITDA | -$49.06M | -$38.70M | -$41.48M | -$25.70M | $46.40M |
| EPS (basic) | -35.25 | -37.22 | -1.20 | -0.45 | 1.27 |
| EPS (diluted) | -35.25 | -37.22 | -1.20 | -0.45 | 1.23 |
| Weighted avg. shares (diluted) | 1.33M | 1.01M | 29.35M | 31.48M | 29.90M |
| Balance sheet | |||||
| Cash & equivalents | $11.88M | $2.94M | $14.92M | $22.97M | $88.61M |
| Short-term investments | — | $26.81M | $43.63M | $58.29M | $1.26M |
| Receivables | $190,375 | $132,570 | $303,926 | $3.45M | $20.84M |
| Inventory | $992,397 | $1.07M | $1.66M | $5.31M | $2.00M |
| Current assets | $13.69M | $32.29M | $62.14M | $92.73M | $115.12M |
| PP&E, net | $2.27M | $2.76M | $3.04M | $2.54M | $1.93M |
| Goodwill | — | — | — | — | $14.71M |
| Intangibles | $7.22M | $26.10M | $26.40M | $26.77M | $27.20M |
| Total assets | $24.74M | $63.56M | $95.32M | $123.09M | $160.03M |
| Current liabilities | $3.54M | $7.32M | $5.75M | $3.87M | $12.60M |
| Total liabilities | $4.11M | $9.69M | $9.31M | $8.57M | $25.56M |
| Shareholders' equity | $20.63M | $53.88M | $85.58M | $114.52M | $134.48M |
| Shares outstanding | 2.10M | 1.10M | 31.26M | 30.87M | 33.82M |
| Cash flow statement | |||||
| Operating cash flow | -$29.14M | -$29.16M | -$22.08M | $6.57M | $41.08M |
| Capital expenditure | $700,047 | $748,352 | $1.37M | $1.43M | $669,463 |
| Free cash flow | -$29.84M | -$29.90M | -$23.45M | $5.14M | $40.41M |
| Investing cash flow | $26.27M | $17.07M | $15.39M | -$58.17M | $4.10M |
| Financing cash flow | $11.81M | $103,914 | -$1.36M | -$14.03M | $450,398 |
| Depreciation & amortization | $1.11M | $1.38M | $1.23M | $1.28M | $335,363 |
| Stock-based compensation | $2.25M | $5.43M | $8.34M | $7.54M | $5.51M |
| Share buybacks | — | — | $1.36M | $14.21M | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.